Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company Read more
REGENXBIO and Nippon Shinyaku Form Exclusive Partnership to Develop RGX-121 and RGX-111 for MPS Diseases Read more
Solid Biosciences Receives FDA IND Clearance for Dual Route Gene Therapy in Friedreich’s Ataxia Read more